(Albany, New York)- 5th Sep 2026, DelveInsight’s Sarcoidosis Market Insights, Epidemiology, and Market Forecast 2036 report delivers an in-depth understanding of Sarcoidosis, historical and forecasted epidemiology, as well as Sarcoidosis market trends across the United States, EU4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan.
The Sarcoidosis Market Report provides real-world prescription pattern analysis, emerging therapies, market share of individual treatments, and historical and forecasted 7MM Sarcoidosis market size from 2022 to 2036. The report also covers current treatment practices, clinical trials, unmet medical needs, market drivers, barriers, and competitive intelligence to help stakeholders identify future growth opportunities.
Get a detailed understanding of the evolving Sarcoidosis treatment landscape: https://www.delveinsight.com/report-store/sarcoidosis-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=mpr
Key Facts of the Sarcoidosis Market Report
The Sarcoidosis market is anticipated to witness steady growth during the forecast period (2026–2036), driven by increasing diagnosis rates, improved disease awareness, expanding clinical development activity, and growing investment in targeted immunomodulatory therapies.
The leading Sarcoidosis companies developing therapies include Kyorin Pharmaceutical, aTyr Pharma, Priovant Therapeutics, Molecure, Xentria, and others.
Current treatment primarily relies on corticosteroids and off-label immunosuppressive therapies, while significant unmet needs remain for disease-specific and steroid-sparing treatment options.
Acthar Gel remains the only FDA-approved therapy specifically indicated for symptomatic pulmonary sarcoidosis.
Emerging therapies such as Efzofitimod (KRP-R120), Brepocitinib, OATD-01, and XTMAB-16 are expected to reshape the Sarcoidosis treatment landscape over the coming years.
Increasing orphan drug incentives, Fast Track designations, and growing pipeline momentum are expected to create new commercial opportunities in the Sarcoidosis therapeutics market.
Request a sample PDF to explore comprehensive Sarcoidosis market forecasts, epidemiology insights, competitive intelligence, and emerging therapy analysis through 2036.
Sarcoidosis Overview
Sarcoidosis is a rare, multisystem inflammatory disease characterized by the formation of non-caseating granulomas in affected organs. Although its exact cause remains unknown, the disease is believed to result from an abnormal immune response triggered by genetic, environmental, or infectious factors in susceptible individuals.
Sarcoidosis most commonly affects the lungs and intrathoracic lymph nodes, but it can also involve the skin, eyes, liver, heart, kidneys, and nervous system. Clinical presentation ranges from asymptomatic disease to chronic progressive organ dysfunction.
Explore how targeted immunomodulatory therapies are transforming the future of the Sarcoidosis market: https://www.delveinsight.com/report-store/sarcoidosis-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=mpr
Sarcoidosis Therapies and Key Companies
Key Sarcoidosis Companies Include:
Kyorin Pharmaceutical
aTyr Pharma
Priovant Therapeutics
Molecure
Xentria
Others
Discover detailed company profiles, pipeline strategies, licensing activities, and competitive benchmarking in DelveInsight’s Sarcoidosis Market Report:https://www.delveinsight.com/report-store/sarcoidosis-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=mpr
Sarcoidosis Current Treatment Landscape
Current Sarcoidosis treatment focuses on reducing inflammation, preventing organ damage, and improving quality of life. Treatment selection depends on disease severity, organ involvement, and the risk of long-term complications.
Prednisone remains the first-line treatment for symptomatic or progressive Sarcoidosis and continues to be the cornerstone of disease management.
Methotrexate, azathioprine, and mycophenolate mofetil are commonly used as steroid-sparing agents for patients requiring long-term treatment or those who cannot tolerate corticosteroids.
TNF-alpha inhibitors, particularly infliximab, are used in severe, chronic, or treatment-resistant Sarcoidosis cases where conventional therapies are insufficient.
Acthar Gel (repository corticotropin injection), marketed by Mallinckrodt Pharmaceuticals, is currently the only FDA-approved therapy specifically indicated for symptomatic pulmonary sarcoidosis.
Sarcoidosis Emerging Therapies
Efzofitimod is a novel immunomodulatory biologic targeting neuropilin-2 (NRP2) to regulate activated myeloid cells. The therapy has received Orphan Drug Designation and Fast Track Designation for pulmonary sarcoidosis and is advancing toward Phase III clinical development.
Brepocitinib is an investigational oral TYK2/JAK1 inhibitor being developed for cutaneous sarcoidosis. Positive Phase II BEACON study results support planned Phase III development in 2026.
OATD-01 is a first-in-class dual CHIT1 inhibitor being evaluated in Phase II development for pulmonary sarcoidosis with the goal of modifying granulomatous inflammation and fibrosis.
XTMAB-16 is an investigational anti-TNF-alpha monoclonal antibody in Phase I/II development for pulmonary sarcoidosis and has demonstrated encouraging safety and preliminary efficacy signals.
Sarcoidosis Market Drivers
High unmet need in chronic and treatment-refractory Sarcoidosis.
Growing clinical development activity and expanding therapeutic pipeline.
Increasing investment from biotechnology and pharmaceutical companies.
Favorable orphan drug incentives and expedited regulatory pathways.
Rising focus on targeted immunomodulatory and disease-modifying therapies.
Sarcoidosis Market Barriers
Limited availability of approved disease-specific therapies.
Long-term dependence on corticosteroids and associated toxicity.
Absence of validated diagnostic biomarkers.
Challenges in managing extrapulmonary Sarcoidosis manifestations.
Disease relapse and variability in treatment response across patients.
Request a sample PDF and evaluate Sarcoidosis market insight: https://www.delveinsight.com/report-store/sarcoidosis-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=mpr
Scope of the Sarcoidosis Market Report
Study Period: 2022–2036
Historical Period: 2022–2025
Base Year: 2025
Forecast Period: 2026–2036
Coverage: 7MM (United States, EU4 – Germany, France, Italy, Spain, the United Kingdom, and Japan)
Key Sarcoidosis Companies: Kyorin Pharmaceutical, aTyr Pharma, Priovant Therapeutics, Molecure, Xentria, and others.
Therapeutic Assessment: Current standard of care, marketed therapies, and emerging Phase III and Phase II pipeline therapies.
Market Dynamics: Market drivers, barriers, opportunities, pricing, and future trends.
Competitive Intelligence Analysis: SWOT Analysis, Conjoint Analysis, Market Entry Strategies, KOL Views, Analyst Views, and Reimbursement Analysis.
Additional Coverage: Epidemiology, Patient Population, Drug Uptake, Clinical Trials, Market Access, and Unmet Needs.
Discover the latest Sarcoidosis Market Landscape: https://www.delveinsight.com/report-store/sarcoidosis-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=mpr
About DelveInsight
DelveInsight is a leading Business Consulting and Market Research firm focused exclusively on the life sciences industry. The company provides comprehensive market intelligence, competitive intelligence, epidemiology forecasting, pipeline assessment, pricing and reimbursement analysis, and healthcare consulting services that help pharmaceutical, biotechnology, and medical device companies accelerate strategic decision-making and commercial success.
Media ContactCompany Name: DelveInsightContact Person: Mehul MalhotraEmail: Send EmailPhone: 09650213330Address:A-1 NV 89107City: delhiState: IndianaCountry: IndiaWebsite: https://www.delveinsight.com/
